Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17373

Veronica Cañón, Jose Luis López-Guerra, Ander Arteagoitia, Olga Del Hoyo, Fernan Suarez, David Büchser, Alfonso Gómez-Iturriaga, Arturo Navarro-Martin, Roberto Ortiz DE Zarate, Jose Fernando Pérez Azorín, Dirk Rades, Jon Cacicedo

{"title":"Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.","authors":"Veronica Cañón, Jose Luis López-Guerra, Ander Arteagoitia, Olga Del Hoyo, Fernan Suarez, David Büchser, Alfonso Gómez-Iturriaga, Arturo Navarro-Martin, Roberto Ortiz DE Zarate, Jose Fernando Pérez Azorín, Dirk Rades, Jon Cacicedo","doi":"10.21873/anticanres.17373","DOIUrl":null,"url":null,"abstract":"Background/aim: Many patients with non-small cell lung cancer (NSCLC) receive palliative radiotherapy (RT). Several factors were analyzed to aid in prescribing an optimal treatment for these patients.Patients and methods: This prospective observational multicenter study investigated several potential factors for associations with overall survival (OS) in 61 patients with NSCLC receiving palliative RT with or without chemotherapy (CT). Investigated factors included age, sex, performance status, history of smoking or alcohol, hemoglobin, co-morbidities, different clinical symptoms, and quality-of-life aspects.Results: Median OS was 10.8 months, and OS rates at 6, 12, and 24 months were 58.5%, 42.5%, and 28.4%, respectively. On multivariate analysis, RT alone (without CT), RT doses ≤30 Gy, advanced tumor stage (stage IV), and poor emotional functioning at diagnosis were associated with significantly worse OS.Conclusion: Patients with NSCLC assigned to palliative RT may benefit from RT doses >30 Gy and additional CT. Sequential CT appears preferable, since concurrent CT increases esophageal toxicity.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5477-5484"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17373","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Many patients with non-small cell lung cancer (NSCLC) receive palliative radiotherapy (RT). Several factors were analyzed to aid in prescribing an optimal treatment for these patients.

Patients and methods: This prospective observational multicenter study investigated several potential factors for associations with overall survival (OS) in 61 patients with NSCLC receiving palliative RT with or without chemotherapy (CT). Investigated factors included age, sex, performance status, history of smoking or alcohol, hemoglobin, co-morbidities, different clinical symptoms, and quality-of-life aspects.

Results: Median OS was 10.8 months, and OS rates at 6, 12, and 24 months were 58.5%, 42.5%, and 28.4%, respectively. On multivariate analysis, RT alone (without CT), RT doses ≤30 Gy, advanced tumor stage (stage IV), and poor emotional functioning at diagnosis were associated with significantly worse OS.

Conclusion: Patients with NSCLC assigned to palliative RT may benefit from RT doses >30 Gy and additional CT. Sequential CT appears preferable, since concurrent CT increases esophageal toxicity.

查看原文本刊更多论文

放疗剂量对非小细胞肺癌姑息治疗患者生存的影响：一项多中心前瞻性研究的结果

背景/目的：许多非小细胞肺癌（NSCLC）患者接受姑息放疗（RT）。几个因素进行了分析，以帮助处方的最佳治疗这些患者。患者和方法：这项前瞻性观察性多中心研究调查了61例接受姑息性放疗伴或不伴化疗（CT）的非小细胞肺癌患者总生存期（OS）相关的几个潜在因素。调查的因素包括年龄、性别、运动状态、吸烟或饮酒史、血红蛋白、合并症、不同临床症状和生活质量方面。结果：中位OS为10.8个月，6、12和24个月的OS率分别为58.5%、42.5%和28.4%。在多因素分析中，单纯放疗（不含CT）、放疗剂量≤30 Gy、肿瘤分期晚期（IV期）和诊断时情绪功能差与OS显著恶化相关。结论：接受姑息性放疗的非小细胞肺癌患者可能受益于放疗剂量为100 ~ 30 Gy和额外的CT。序贯CT更可取，因为同时CT可增加食道毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.